We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
+27.84%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$286M
AUM Growth
+$39.5M
(+16%)
Cap. Flow
-$15.3M
Cap. Flow
% of AUM
-5.33%
Top 10 Holdings %
Top 10 Hldgs %
99.99%
Holding
15
New
3
Increased
2
Reduced
3
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$6.46M |
| 2 |
Denali Therapeutics
DNLI
|
+$4.49M |
| 3 |
uniQure
QURE
|
+$1.66M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
+$218K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AIMT
Aimmune Therapeutics
AIMT
|
+$23.2M |
| 2 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
+$1.87M |
| 3 |
DERM
Dermira, Inc.
DERM
|
+$1.58M |
| 4 |
OREX
Orexigen Therapeutics, Inc.
OREX
|
+$1.11M |
| 5 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$249K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
| $117M | 40.96% |
3,100,146
-720,316
| -19% | -$23.2M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $99.9M | 34.92% |
1,672,714
| – | – |
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $19.6M | 6.83% |
1,558,108
+15,000
| +1% | +$218K |
|
|
4
Insmed
INSM
$23B
| $16.2M | 5.65% |
518,645
+218,645
| +73% | +$6.46M |
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
| $12M | 4.18% |
1,043,832
| – | – |
|
|
XLRN
6
DELISTED
Acceleron Pharma
XLRN
| $10.4M | 3.63% |
244,756
| – | – |
|
|
7
Denali Therapeutics
DNLI
$3.76B
| $3.91M | 1.37% |
+250,000
| New | +$4.49M |
|
|
JUNO
8
DELISTED
Juno Therapeutics, Inc.
JUNO
| $3.88M | 1.36% |
85,000
-5,000
| -6% | -$249K |
|
|
9
uniQure
QURE
$2.68B
| $2.14M | 0.75% |
+109,350
| New | +$1.66M |
|
|
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
| $1M | 0.35% |
11,900
-2,400
| -17% | -$200K |
|
|
ALDR
11
CALL
DELISTED
Alder Biopharmaceuticals
ALDR
| $40K | 0.01% |
+24,000
| New | +$268K |
|
12
Larimar Therapeutics
LRMR
$396M
| – | – |
-2,565
| Closed | -$108K |
|
|
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| – | – |
-119,912
| Closed | -$1.87M |
|
|
DERM
14
DELISTED
Dermira, Inc.
DERM
| – | – |
-58,624
| Closed | -$1.58M |
|
|
OREX
15
DELISTED
Orexigen Therapeutics, Inc.
OREX
| – | – |
-523,132
| Closed | -$1.11M |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q4 2017 Portfolio in Review
As of Q4 2017, Foresite Capital Management II held 15 positions worth $286M, up 16% from $247M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management II withdrew a net $15.3M in Q4 2017, closing 4 positions and reducing 3 holdings. Its most notable exit was Jounce Therapeutics, Inc. Common Stock, an estimated $1.87M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 26% a quarter earlier.
Against the trend, Foresite Capital Management II opened a new position in Denali Therapeutics worth $3.91M.
- Foresite Capital Management II's largest Q4 2017 buy was Denali Therapeutics: 250,000 shares worth $3.91M.
- Foresite Capital Management II added most to Insmed in Q4 2017, an estimated $6.46M increase.
- Foresite Capital Management II's biggest Q4 2017 reduction was Aimmune Therapeutics, cutting an estimated $23.2M.
- Foresite Capital Management II fully exited Jounce Therapeutics, Inc. Common Stock in Q4 2017, selling an estimated $1.87M.
- Foresite Capital Management II's ten largest holdings make up 100% of its $286M portfolio in Q4 2017.
- Foresite Capital Management II opened 3 new positions and closed 4 in Q4 2017.
- Foresite Capital Management II's portfolio value rose 16% quarter-over-quarter to $286M.
Based on Foresite Capital Management II's 13F filing for Q4 2017, filed 13 Feb 2018.